GlassScriptPhysician profile
Akash Garg
NPI 1033671615
$2,766.84
in general payments reported to CMS, 2019-2025
23 companies · $706 in 2025
The $706 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.61 · 2022: $150 · 2023: $916 · 2024: $974 · 2025: $706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,596.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,595.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $646.23 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $291.94 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $276.83 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $235.12 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $223.28 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $148.33 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $122.00 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $121.91 | 2023-2024 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $106.19 | 2023-2024 | |
| Exact Sciences Corporation | $97.95 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $79.89 | 2025 | Repatha, Otezla, Evenity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $78.15 | 2022 | |
| Pfizer INC. | $60.29 | 2023-2025 | |
| Optinose US, INC. | $54.67 | 2024 | |
| Abbott Laboratories | $48.72 | 2024 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.01 | 2023 | Sunosi |
| Alexion Pharmaceuticals, INC. | $25.16 | 2023 | Ultomiris |
| Kci USA, INC. | $25.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.85 | 2024 | |
| Celgene Corporation | $20.61 | 2021 | |
| Indivior INC. | $20.07 | 2024 | Sublocade |
| Sanofi-Aventis U.S. LLC | $19.79 | 2023 | |
| Amarin Pharma, INC. | $16.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Akash Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.